Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prospective study on the [<sup>18</sup>F]FDOPA PET/CT role in the management of medullary thyroid cancer patients with high residual calcitonin level after surgery.

European journal of nuclear medicine and molecular imaging·2026
Same author

A computational framework for optimizing radioiodine therapy protocols in metastatic thyroid cancer.

Scientific reports·2026
Same author

Correction: A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217).

BMC cancer·2026
Same author

Role of <sup>18</sup>F-PSMA PET/MRI in Prostate Cancer Recurrence After Prostatectomy.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

[<sup>177</sup>Lu]Lu-dota-tate versus sunitinib in patients with metastatic progressive neuroendocrine tumours of the pancreas (OCLURANDOM): a randomised, controlled, phase 2 trial.

The Lancet. Oncology·2026
Same author

New Paradigms in Theranostics of Prostate Cancer: The Rise of α-Emitters and Next-generation Targets.

European urology focus·2026
Same journal

Overall Survival with [<sup>177</sup>Lu]Lu-PSMA-617 Versus [<sup>177</sup>Lu]Lu-PSMA I&T: A Propensity Score-Matched Real-World Analysis.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same journal

Toward a Biopsy-Free Diagnosis of Prostate Cancer: Potential of Combined <sup>18</sup>F-Flotufolastat PSMA PET and mpMRI.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same journal

PSMA PET/CT-Targeted Biopsy in Men with Negative or Equivocal Multiparametric MRI and Exploratory Dynamic Total-Body PET: The FUPERMAN Study.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same journal

Erratum.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same journal

Live from 2026 SNMMI Annual Meeting in Los Angeles!

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same journal

CAR T-Cell Therapy for Cancer: Updates and Challenges for Response Assessment.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
See all related articles

Related Experiment Video

Updated: May 23, 2026

Live Imaging to Quantify Cellular Radiosensitivity in Patient-Derived Tumor Organoids
05:39

Live Imaging to Quantify Cellular Radiosensitivity in Patient-Derived Tumor Organoids

Published on: April 5, 2024

Radiopharmaceutical Therapy Meets Radiobiology: Implications for Trial Design and DNA Repair Inhibitor Combinations.

Katharina Lückerath1, Pablo Mínguez Gabiña2, Uta Eberlein3

  • 1Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium-University Hospital Essen, Essen, Germany; katharina.lueckerath@uk-essen.de jean-pierre.pouget@inserm.fr.

Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|May 21, 2026
PubMed
Summary
This summary is machine-generated.

Radiopharmaceutical therapy (RPT) efficacy may be limited by DNA repair. Combining 177Lu-RPT with DNA damage response (DDR) inhibitors could improve outcomes by disrupting repair during treatment.

Keywords:
DNA damage repairbiomarkerscombination therapylinear quadratic modelradiobiologyradiopharmaceutical therapy

More Related Videos

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes
08:32

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes

Published on: May 23, 2025

Immunofluorescence Imaging of DNA Damage and Repair Foci in Human Colon Cancer Cells
05:18

Immunofluorescence Imaging of DNA Damage and Repair Foci in Human Colon Cancer Cells

Published on: June 9, 2020

Related Experiment Videos

Last Updated: May 23, 2026

Live Imaging to Quantify Cellular Radiosensitivity in Patient-Derived Tumor Organoids
05:39

Live Imaging to Quantify Cellular Radiosensitivity in Patient-Derived Tumor Organoids

Published on: April 5, 2024

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes
08:32

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes

Published on: May 23, 2025

Immunofluorescence Imaging of DNA Damage and Repair Foci in Human Colon Cancer Cells
05:18

Immunofluorescence Imaging of DNA Damage and Repair Foci in Human Colon Cancer Cells

Published on: June 9, 2020

Area of Science:

  • Radiobiology
  • Oncology
  • Nuclear Medicine

Background:

  • Radiopharmaceutical therapy (RPT) delivers low-dose rate radiation, potentially allowing cancer cells to repair DNA damage.
  • Cellular DNA repair capacity can limit the effectiveness of RPT, particularly 177Lu-labeled RPT (177Lu-RPT).

Purpose of the Study:

  • To explore how radiobiology principles, especially DNA damage response (DDR), can guide the design of 177Lu-RPT clinical trials.
  • To emphasize combinations of 177Lu-RPT with DDR inhibitors and replication stress response (RSR) inhibitors.

Main Methods:

  • Integration of preclinical and clinical data on DNA damage induction and repair during 177Lu-RPT.
  • Analysis of combinations of 177Lu-RPT with DDR/RSR pathway inhibitors.

Main Results:

  • Low dose rates in 177Lu-RPT (<0.1 Gy/h) mean sublethal DNA damage is repaired during exposure, reducing the quadratic component (β) of cell killing.
  • Intrinsic radiosensitivity (α) becomes the primary factor in cell killing, highlighting the need to understand biological determinants of sensitivity.
  • Questions arise regarding optimal activity per cycle and treatment cycle number.

Conclusions:

  • 177Lu-RPT efficacy can be enhanced by combining it with DDR and RSR inhibitors to interfere with simultaneous DNA repair.
  • Rational design and sequencing of these combinations are crucial.
  • Optimizing combinations requires integrating tumor/patient radiosensitivity, dosimetry, and biomarker endpoints into trial designs.